Our results suggest that a significant number of cancers weredetected below 1.5 ng / ml of PSA.Conclusion: A significant number of prostate cancers are found below 1.5 ng / mlPSA.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objectives: Prostate specific antigen (PSA) is the most commonly used markerfor prostate cancer.
📊
Key Findings & Data:PSA-based screening has reduced disease-specific mortality.However, PSA is not specific for prostate cancer, but is specific for prostate tissue andincreases in benign conditions.Material and Methods: In our study, 63 patients with PSA values of 1.5 ng / ml or lesswere evaluated retrospectively with 636 patients who underwent prostate samplingbecause of the suspicion of prostate cancer.Results: In our study, 34.9% prostate cancer and 4.1% ASAP were detected below1.5 ng / ml of PSA.
💡
Conclusion & Impact:Our results suggest that a significant number of cancers weredetected below 1.5 ng / ml of PSA.Conclusion: A significant number of prostate cancers are found below 1.5 ng / mlPSA.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Prostate cancer · Prostate Specific Antigen · Prostate Biopsy
Abstract
Objectives: Prostate specific antigen (PSA) is the most commonly used markerfor prostate cancer. PSA-based screening has reduced disease-specific mortality.However, PSA is not specific for prostate cancer, but is specific for prostate tissue andincreases in benign conditions.Material and Methods: In our study, 63 patients with PSA values of 1.5 ng / ml or lesswere evaluated retrospectively with 636 patients who underwent prostate samplingbecause of the suspicion of prostate cancer.Results: In our study, 34.9% prostate cancer and 4.1% ASAP were detected below1.5 ng / ml of PSA. Our results suggest that a significant number of cancers weredetected below 1.5 ng / ml of PSA.Conclusion: A significant number of prostate cancers are found below 1.5 ng / mlPSA. The lack of a PSA value that we can say without prostate cancer leads to theneed for a low cost and reliable marker.
Turan, G., Aslan, F., Paksoy, S., Altun, E. (2022). Histopathological Results in Patients With Prostate Specific Antigen Below 1.5 ng / ml. Clinical and Experimental Health Sciences, Cilt: 8 - Sayı: 3, 207–210. https://ajindex.com/articles/474386
Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, et al. Early Stage Prostate Cancer An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016; 96: 116-120.